Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy

References

• Yamada M, Li AW, Wall JR. Thyroid-associated ophthalmopathy: Clinical features, pathogenesis, and management. Crit Rev Clin Lab Sci 2000; 37: 523–549
   PubMed Web of Science ®Google Scholar
• El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy: A practical guide to classification, natural history and management. Intern Med J 2004; 34: 482–491
   PubMed Web of Science ®Google Scholar
• Burch HB, Wartofsky L. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747–793
   PubMed Web of Science ®Google Scholar
• Gopinath B, Adams CL, Musselman R, Tani J, Wall JR. Antibodies against calsequestrin and type XIII collagen are good markers for chronic upper eyelid retraction. Ocul Immunol Inflamm 2007; 15: 81–88
   PubMed Web of Science ®Google Scholar
• Gopinath B, Musselman R, Adams CL, Tani J, Beard N, Wall JR. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy—correlation with clinical features. Thyroid 2006; 16: 967–974
   PubMed Web of Science ®Google Scholar
• Gopinath B, Musselman R, Beard N, El-Kaissi S, Tani J, Adams CL, Wall JR. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease. Clin Exp Immunol 2006; 145: 56–62
   PubMed Web of Science ®Google Scholar
• Tani J, Wall JR. Autoimmunity against eye-muscle antigens may explain thyroid-associated ophthalmopathy. CMAJ 2006; 175: 239
   PubMed Web of Science ®Google Scholar
• Weetman AP, Cohen S, Gatter KC, Fells P, Shine B. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989; 75: 222–227
   PubMed Web of Science ®Google Scholar
• Pappa A, Lawson JM, Calder V, Fells P, Lightman S. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol 2000; 84: 517–522
   PubMed Web of Science ®Google Scholar
• Forster G, Otto E, Hansen C, Ochs K, Kahaly G. Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin Exp Immunol 1998; 112: 427–434
   PubMed Web of Science ®Google Scholar
• de Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, Romagnani S, del Prete G. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 1993; 77: 1120–1124
   PubMed Web of Science ®Google Scholar
• Kahaly G, Stover C, Otto E, Beyer J, Schuler M. Glycosaminoglycans in thyroid-associated ophthalmopathy. Autoimmunity 1992; 13: 81–88
   PubMed Web of Science ®Google Scholar
• Hansen C, Otto E, Kuhlemann K, Forster G, Kahaly GJ. Glycosaminoglycans in autoimmunity. Clin Exp Rheumatol 1996; 14: S59–S67
   PubMed Web of Science ®Google Scholar
• Otto E, Ochs K, Leyendecker E, Gentsch A, Hansen C, Beyer J, Kahaly G. Autoimmune endocrine ophthalmopathy and retrobulbar antigens. Horm Metab Res 1995; 27: 533–538
   PubMed Web of Science ®Google Scholar
• Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1996; 81: 449–452
   PubMed Web of Science ®Google Scholar
• Otto EA, Ochs K, Hansen C, Wall JR, Kahaly GJ. Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens. J Clin Endocrinol Metab 1996; 81: 3045–3050
   PubMed Web of Science ®Google Scholar
• Wall JR, Trewin A, Fang SL, Ingbar SH, Braverman LE. Studies of immunoreactivity to human lacrimal gland fractions in patients with ophthalmic Graves' disease. J Endocrinol Invest 1978; 1: 253–258
   PubMed Web of Science ®Google Scholar
• Wall JR, Walters BA, Grant C. Leukocyte adherence inhibition in response to human orbital and lacrimal extracts in patients with Graves' ophthalmopathy. J Endocrinol Invest 1979; 2: 375–378
   PubMed Web of Science ®Google Scholar
• Arnold K, Tandon N, McIntosh RS, Elisei R, Ludgate M, Weetman AP. T cell responses to orbital antigens in thyroid-associated ophthalmopathy. Clin Exp Immunol 1994; 96: 329–334
   PubMed Web of Science ®Google Scholar
• Chang CH, Yamada M, Blanchard ME, Li AW, Wall JR. Peripheral blood lymphocyte transformation to G2s in patients with autoimmune thyroid disease with and without ophthalmopathy. Autoimmunity 2002; 35: 313–317
   PubMed Web of Science ®Google Scholar
• Gunji K, Kubota S, Stolarski C, Wengrowicz S, Kennerdell JS, Wall JR. A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin. Autoimmunity 1999; 29: 1–9
   PubMed Web of Science ®Google Scholar
• Kubota S, Gunji K, Ackrell BA, et al. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: The corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 443–447
   PubMed Web of Science ®Google Scholar
• Gunji K, De Bellis A, Li AW, et al. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: Autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1641–1647
   PubMed Web of Science ®Google Scholar
• Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg 1993; 9: 77–82
   PubMed Web of Science ®Google Scholar
• Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach. Br J Ophthalmol 1989; 73: 639–644
   PubMed Web of Science ®Google Scholar
• Paschke R, Vassart G, Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995; 42: 565–569
   PubMed Web of Science ®Google Scholar
• Bahn RS. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab 2003; 88: 1939–1946
   PubMed Web of Science ®Google Scholar
• Porter JD, Khanna S, Kaminski HJ, et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001; 98: 12062–12067
   PubMed Web of Science ®Google Scholar
• Fliegel L, Burns K, Wlasichuk K, Michalak M. Peripheral membrane proteins of sarcoplasmic and endoplasmic reticulum. Comparison of carboxyl-terminal amino acid sequences. Biochem Cell Biol 1989; 67: 696–702
   PubMed Web of Science ®Google Scholar
• De Bellis A, Sansone D, Coronella C, et al. Serum antibodies to collagen XIII: A further good marker of active Graves' ophthalmopathy. Clin Endocrinol 2005; 62: 24–29
   PubMed Web of Science ®Google Scholar
• De Bellis A, Sansone D, Coronella C, et al. Serum antibodies to collagen XIII: A further good marker of active Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2005; 62: 24–29
   PubMed Web of Science ®Google Scholar